Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
https://doi.org/10.29413/ABS.2018-3.1.18
Abstract
Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the developing of NAFLD is a dysfunction of hematolymphatic barrier and linagliptin showed positive effect on this. The group of inhibitors of apoptosis - Bcl-2 resists to wide variety of pro-apoptotic proteins. Studying correction of apoptosis can be the key to the treatment of NAFLD, and that is a reason of high interest in anti-apoptotic Bcl-2 protein. Aims. To assess the features of the expression of the anti-apoptotic Bcl-2 protein in the liver of db/db mice in the model of obesity and type 2 diabetes mellitus and with linaglyptin correction. Materials and methods. Experiment was performed on type 11 (db/db) diabetic mice. Linaglyptin or placebo was administered daily by gavage from the 8th to 16th weeks of life. Results. The week immunohistochemical reaction for antiapoptotic protein Bcl-2 was found in placebo-treated mice. Whereas treatment with Linaglyptin shifted the ratio of apoptosis regulators following significant increase in the area of Bcl-2 expression. Conclusions. The obtained results demonstrate a "try" at antiapoptotic activity of the Linaglyptin in the liver in the model of T2D.
About the Author
M. A. Cherepanova
Scientific Institute of Clinical and Experimental Lymphology
Russian Federation
Russian Federation
References
1. Мичурина С.В., Архипов С.А., Колесников С.И. Особенности апоптоза гепатоцитов крыс при воздействии бенз(а)пирена // Клеточные технологии в биологии и медицине. - 2014. - № 3. - С. 174-177
2. Aroor A.R., Sowers J.R., Jia G., DeMarco V.G. (2014). Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. Am J Physiol Heart Circ Physiol, 307, 477-492.
3. Bechmann L.P., Gieseler R.K., Sowa J.P., Kahraman A., Erhard J., Wedemeyer I., Emons B., Jochum C., Feldkamp T., Gerken G., Canbay A. (2010). Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int, 30, 850-859.
4. Itou M., Kawaguchi T., Taniguchi E., Sata M. (2013). Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol, 19 (15), 2298-2306. doi: 10.3748/wjg.v19.i15.2298
5. Kern M., Klöting N. Niessen H.G., Thomas L., Stiller D., Mark M., Klein T., Blüher M. (2012). Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One, 7 (6), e38744. doi: 10.1371/journal.pone.0038744.
6. Manrique C., Habibi J., Aroor A.R., Sowers J.R., Jia G., Hayden M.R., Garro M., Martinez-Lemus L.A., Ramirez-Perez F.I., Klein T., Meininger G.A., DeMarco V.G. (2016). Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc Diabetol, 15, 94. doi: 10.1186/s12933-016-0414-5.
7. Michurina S.V., Ischenko I.Ju., Klimontov V.V., Archipov S.A., Myakina N.E., Cherepanova M.A., Zavjalov E.L., Koncevaya G.V., Konenkov V.I. (2016). Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes, 7 (19), 534-546.
8. Negrini S., Gorgoulis V.G., Halazonetis T.D. (2010). Genomic instability - an evolving hallmark of cancer. Nat Rev Mol Cell Biol, 11 (3), 220-228. doi: 10.1038/nrm2858.
9. Nolan C.J., Larter C.Z. (2009). Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it? J Gastroenterol Hepatol, 24, 703-706. doi: 10.1111/j.1440-1746.2009.05823.x.
10. Orrenius S. (2007). Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev, 39, 443-455.
11. Rolo A.P., Teodoro J.S., Palmeira C.M. (2012). Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med, 52, 59-69.
12. Ryu S.Y., Peixoto P.M., Teijido O., Dejean L.M., Kinnally K.W. (2010). Role of mitochondrial ion channels in cell death. Biofactors, 36, 255-263. doi: 10.1002/biof.101.
13. Shah P., Schumann D.M., Ardestani A., Shu L., Paroni F., Kerr-Conte J., Pattou F., Klein T., Maedler K. (2013). The DPP-4 Inhibitor linagliptin restores ß cell function and survival in human isolated islets. J Clin Endocrinol Metab, 98 (7), E1163-72. doi: 10.1210/jc.2013-1029.
14. Yang K.C., Hung H.F., Lu C.W., Chang H.H., Lee L.T., Huang K.C. (2016). Association of non-alcoholic fatty liver disease with metabolic syndrome independently of central obesity and insulin resistance. Sci Rep, 6, 27-34. doi: 10.1038/srep27034.
Review
For citations:
Cherepanova M.A. Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction. Acta Biomedica Scientifica. 2018;3(1):116-119. (In Russ.) https://doi.org/10.29413/ABS.2018-3.1.18
Views:
711
.png)
Email this article 
